{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:09:04Z","timestamp":1784549344317,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2025.12.015","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:40:20Z","timestamp":1772109620000},"page":"110979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-6212","authenticated-orcid":false,"given":"Neil J.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Sura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Conkling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojkumar","family":"Bupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Vickery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.12.015_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0002","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.euros.2023.04.015","article-title":"The metastatic risk of renal cell carcinoma by primary tumor size and subtype","volume":"52","author":"Monda","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0003","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Kidney and Renal Cancer. 2026; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"10.1016\/j.urolonc.2025.12.015_bib0004","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0005","doi-asserted-by":"crossref","first-page":"459 e1","DOI":"10.1016\/j.urolonc.2023.08.009","article-title":"Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab","volume":"41","author":"Shah","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0006","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","article-title":"Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era","volume":"49","author":"Shah","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0007","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0008","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0009","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41416-018-0164-0","article-title":"Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"119","author":"Powles","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0010","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0011","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0012","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1470-2045(15)00543-4","article-title":"Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma","volume":"17","author":"Motzer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0013","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0014","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2022.10.017","article-title":"Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations","volume":"83","author":"Fitzgerald","year":"2023","journal-title":"Eur Urol"},{"issue":"27","key":"10.1016\/j.urolonc.2025.12.015_bib0016","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.19.03315","article-title":"Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors","volume":"38","author":"Gul","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0017","doi-asserted-by":"crossref","first-page":"OP2500278","DOI":"10.1200\/OP-25-00278","article-title":"Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes","author":"Shah","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae insights: kidney Cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0019","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.015_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/03008916221138881","article-title":"A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)","volume":"109","author":"Procopio","year":"2023","journal-title":"Tumori"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/03008916221138881","article-title":"A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: the BREAKPOINT trial (Meet-Uro trial 03)","volume":"109","author":"Procopio","year":"2023","journal-title":"Tumori"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0022","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0024","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0025","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0026","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2025.12.015_bib0027","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cancers16122223","article-title":"Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials","volume":"16","author":"Shah","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.urolonc.2025.12.015_bib0028","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3390\/cancers13236109","article-title":"Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0029","unstructured":"The US Oncology Network. Accessed January 13, 2026, https:\/\/www.usoncology.com\/our-company"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0030","doi-asserted-by":"crossref","first-page":"OP2500278","DOI":"10.1200\/OP-25-00278","article-title":"Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes","author":"Shah","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.urolonc.2025.12.015_bib0031","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3390\/cancers17091434","article-title":"Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies","volume":"17","author":"Shah","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.12.015_bib0032","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2025.43.5_suppl.501","article-title":"Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1\/PD-L1 immuno-oncology (IO) therapies","volume":"43","author":"Neil","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:52:38Z","timestamp":1784548358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143925004983"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110979"}}